Sapreme Appoints Henrik Luessen as Chief Business Officer Sapreme, a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutics, today announced the appointment of Henrik L. Luessen, Ph.D., as Chief Business Officer. In this role, Dr. Luessen will advise Sapreme in its business development, partnerships and funding activities, and will report to Guy Hermans, Ph.D., Chief Executive Officer. Henrik brings strong experience with emerging biotechnology companies to Sapreme including licensing, portfolio strategy, financing and strategic development which are critical aspects for Sapreme at this stage of development,
commented Guy Hermans, Chief Executive Officer of Sapreme.
Sapreme Appoints Björn Cochlovius as Chairman of its Board of Directors Sapreme, a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutics, today announced the establishment of its independent Board of Directors by the appointment of Björn Cochlovius, Ph.D., as Chairman of the Board, effective immediately. Björn is a pharma industry veteran with both a deep understanding of oncology research and antibody engineering as well as a strong track record of creating value by leading and executing business transactions. Björn s appointment is particularly timely as his extensive knowledge will aid the advancement of our technology platform through late preclinical development. He will be key in advising the Company in ongoing interactions with potential partners and identifying strategic opportunities that will further validate our approach,